Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections.
Infection
; 24(6): 473-9, 1996.
Article
em En
| MEDLINE
| ID: mdl-9007598
ABSTRACT
In an open, randomised, multicentre trial, the efficacy and tolerability of empirical meropenem monotherapy (1 g intravenously every 8 hours) and cefotaxime (2 g every 8 hours) plus metronidazole (0.5 g intravenously every 8 hours) for 5 to 10 days was compared in 94 patients with serious intra-abdominal infection who required surgery. Eighty-three patients had an evaluable clinical response. Significantly more patients in the meropenem group had a satisfactory clinical response at the end of treatment (41/43 [95.3%] vs 30/40 [75.0%]; p = 0.008). The bacteriological response was also higher in the meropenem group (31/33 vs 26/32). In the bacteriologically evaluable population, a satisfactory clinical response was observed in 31/33 of those who received meropenem compared to 24/32 of the cefotaxime/metronidazole recipients (p = 0.03). Empirical meropenem monotherapy should prove a useful alternative to the currently standard combination treatment for serious intraabdominal infections.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Peritonite
/
Cefotaxima
/
Cefalosporinas
/
Tienamicinas
/
Quimioterapia Combinada
/
Infecções
/
Metronidazol
/
Antitricômonas
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Infection
Ano de publicação:
1996
Tipo de documento:
Article
País de afiliação:
Alemanha